SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Scinai Immunotherapeutics Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026
$0.75−0.00 (-0.32%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2015 to 2025
Gross margin
-202.3%
Operating margin
-575.3%
Net margin
-633.6%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +99.2% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -91.9% | |
| Return on assets | – | – | -66.3% | |
| Current ratio | – | 0.17 | 1.30 | |
| Interest coverage | – | – | – | |
| Capex to revenue | – | – | 1.8% | |
| Diluted shares | 135M | 443M | 9.34B |
Where the cash went
Fiscal 2021 to 2025, five years combined
Scinai Immunotherapeutics generated $36.44M from operations and spent $1.65M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$36.44M
Used
$1.65M
Capital expenditure$1.65M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-633.6%
×Asset turnover0.10×
×Equity multiplier1.39×
=Return on equity, FY2025-91.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -633.6% | 0.10× | 1.39× | -91.9% |
| FY2024 | 728.9% | 0.04× | 5.72× | 177.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$8.31M
- Cash generatingOperating cash flow above zero-$6.03M
- Return on assets improvedROA up on the prior year27.4% → -61.8%
- Earnings backed by cashOperating cash flow above net income-$6.03M vs -$8.31M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.32 → 1.30
- No dilutionShare count did not rise3.23B → 9.34B
- Gross margin improvedGross margin up on the prior year-88.15% → -202.29%
- More efficientAsset turnover rose0.04 → 0.10